{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darunavir+%28DRV%29&page=2", "query": { "intervention": "Darunavir (DRV)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Darunavir+%28DRV%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-02T02:27:10.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00524368", "title": "A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus - Type 1" ], "interventions": [ { "name": "Darunavir (DRV)", "type": "DRUG" }, { "name": "Ritonavir (rtv)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2007-10", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524368" }, { "nct_id": "NCT00977756", "title": "IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir (RAL)", "type": "DRUG" }, { "name": "Atazanavir (ATV)", "type": "DRUG" }, { "name": "Ritonavir (RTV)", "type": "DRUG" }, { "name": "Tenofovir (TDF)", "type": "DRUG" }, { "name": "Etravirine (ETV)", "type": "DRUG" }, { "name": "Darunavir (DRV)", "type": "DRUG" }, { "name": "Maraviroc (MVC)", "type": "DRUG" }, { "name": "Lopinavir/ritonavir (LPV/r)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 168, "start_date": "2002-08", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2015-08-07", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00977756" }, { "nct_id": "NCT00811954", "title": "Comparative Study of Three NNRTI-Sparing HAART Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1814, "start_date": "2009-05", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-09-05", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811954" }, { "nct_id": "NCT02616029", "title": "Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2015-12-17", "completion_date": "2019-07-11", "has_results": true, "last_update_posted_date": "2020-07-23", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 3, "location_summary": "Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616029" }, { "nct_id": "NCT03631732", "title": "Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" }, { "name": "Third Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 496, "start_date": "2018-08-28", "completion_date": "2020-08-19", "has_results": true, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631732" }, { "nct_id": "NCT02499978", "title": "Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "Darunavir/Cobicistat", "type": "DRUG" }, { "name": "Dolutegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-05", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2021-07-09", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 2, "location_summary": "Stanford, California • Aurora, Colorado", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02499978" }, { "nct_id": "NCT00543101", "title": "Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Darunavir (DRV/r)", "type": "DRUG" }, { "name": "continue on current dual boosted PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2007-10", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00543101" }, { "nct_id": "NCT02771249", "title": "Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infected Population With Latent Tuberculosis" ], "interventions": [ { "name": "rifapentene (RPT)", "type": "DRUG" }, { "name": "darunavir/cobicistat (DRV/c)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2016-06-03", "completion_date": "2021-08-17", "has_results": false, "last_update_posted_date": "2022-04-18", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771249" }, { "nct_id": "NCT01565850", "title": "D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "D/C/F/TAF", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "D/C/F/TAF Placebo", "type": "DRUG" }, { "name": "DRV Placebo", "type": "DRUG" }, { "name": "COBI Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2012-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-04-11", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01565850" }, { "nct_id": "NCT02285114", "title": "Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "F/TAF", "type": "DRUG" }, { "name": "3rd ARV agent", "type": "DRUG" }, { "name": "Boosted PIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 41, "start_date": "2015-01-20", "completion_date": "2024-12-11", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-02T02:27:10.460Z", "location_count": 4, "location_summary": "Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02285114" } ] }